Patient with Parkinson’s disease and neuropathic pain – case report Case report

Main Article Content

Dariusz Koziorowski

Abstract

Parkinson’s disease is a complex neurodegenerative process involving various structures in the nervous system. Parkinson’s disease is diagnosed mainly on the basis of clinical symptoms resulting from damage to the nigrostriatal pathway, which gives the characteristic motor symptoms. Therefore, traditional symptomatic treatment consists of administering dopamine precursor levodopa with an aromatic amino acid decarboxylase inhibitor or directly stimulating the striatal dopamine receptors. The problem of dopaminergic therapy is the limited influence on the symptoms of the disease, including pain. Central pain is one type of pain that occurs in Parkinson’s disease patients and dopaminergic therapy may be of limited value in treating it. Proper diagnosis of the problem and the application of appropriate chronic pain therapy are essential for the quality of life of patients. The author presents the case of a 65-year-old man with Parkinson’s disease and chronic pain who required modification of dopaminergic treatment and implementation of central neuropathic pain therapy.

Article Details

How to Cite
Koziorowski , D. (2021). Patient with Parkinson’s disease and neuropathic pain – case report. Medycyna Faktow (J EBM), 14(3(52), 318-321. https://doi.org/10.24292/01.MF.0321.15
Section
Articles

References

1. Fearnlay JM, Lees AJ. Aging and Parkinson’s disease: substantia nigra regional selectivity. Brain. 1991; 114: 2283-301.
2. Titova N, Qamar MA, Chaudhuri KR. The Nonmotor Features of Parkinson’s Disease. Int Rev Neurobiol. 2017; 132: 33-54.
3. Antonini A, Stoessl AJ, Kleinman LS et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018; 34(12): 2063-73.
4. Moreno CB, Hernández-Beltrán N, Munévar D et al. Central neuropathic pain in Parkinson’s disease. Neurología. 2012; 27(8): 500-3.
5. Fahn S, Oakes D, Shoulson I et al; Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004; 351(24): 2498-508.
6. Fox SH, Katzenschlager R, Lim SY et al; Movement Disorder Society Evidence-Based Medicine Committee. International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson’s Disease. Mov Disord. 2018; 33(8): 1248-66.
7. Charakterystyka Produktu Leczniczego Madopar (access: 30.08.2021).
8. Charakterystyka Produktu Leczniczego Nakom (access: 30.08.2021).
9. Edinoff A, Sathivadivel N, McBride T et al. Chronic Pain Treatment Strategies in Parkinson’s Disease. Neurol Int. 2020; 12(3): 61-76. http://doi.org/10.3390/neurolint12030014.
10. Sławek J, Bogucki A, Koziorowski D et al. Agoniści dopaminy w leczeniu choroby Parkinsona i zespołu niespokojnych nóg – rekomendacje ekspertów Polskiego Towarzystwa Choroby Parkinsona i Innych Zaburzeń Ruchowych oraz Sekcji Schorzeń Pozapiramidowych Polskiego Towarzystwa Neurologicznego. Pol Prz Neurol. 2016; 12(1): 1-14.
11. Szok D, Tajti J, Nyári A et al. Therapeutic Approaches for Peripheral and Central Neuropathic Pain. Behav Neurol. 2019; 2019: 8685954.
12. Derry S, Bell RF, Straube S et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019; 1(1): CD007076. http://doi.org/10.1002/14651858.CD007076.pub3.
13. Seppi K, Ray Chaudhuri K, Coelho M et al; the collaborators of the Parkinson’s Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson’s disease – an evidence-based medicine review. Mov Disord. 2019; 34(2): 180-98. http://doi.org/10.1002/mds.27602.